AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
Completed
- Conditions
- Moderate-to-Severe Asthma
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06422663
- Locations
- 🇨🇳
Research Site, Zigong, China
A Non-interventional, Prospective Study With Benralizumab
Recruiting
- Conditions
- Asthma, Bronchial
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06422078
- Locations
- 🇩🇪
Research Site, Wurzburg, Germany
FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage
Completed
- Conditions
- InTracranial Haemorrhage
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT06420011
- Locations
- 🇦🇪
Research Site, Al Ain, United Arab Emirates
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
Recruiting
- Conditions
- Asthma
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06419413
- Locations
- 🇨🇳
Research Site, Zhaoqing, China
Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
Recruiting
- Conditions
- PolyneuropathyHereditary Transthyretin AmyloidosisAmyloidosisCarpal Tunnel Syndrome
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 880
- Registration Number
- NCT06414746
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT06417814
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.
Recruiting
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT06417801
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
Phase 1
Terminated
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT06406400
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06388616
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
Active, not recruiting
- Conditions
- HER2-positive Breast CancerMetastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT06386263
- Locations
- 🇨🇦
Research Site, Oakville, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath